[Click eStock] "Deepnoid to Expand Medical AI Solution Supply in Second Half"

Hana Securities stated on the 19th that Deepnoid recorded its highest quarterly sales in the second quarter of this year and expects a turnaround to profitability next year.

Deepnoid posted sales of 3.8 billion KRW and an operating loss of 2.7 billion KRW in the second quarter of this year.

Jo Jeong-hyun, a researcher at Hana Securities, explained, "We recognized sales from Deep Factory for secondary battery customers worth 7.5 billion KRW, which were ordered in the fourth quarter of last year," adding, "It is also understood that sales from Deep Factory for major display companies were reflected."

He added, "It seems that the medical artificial intelligence (AI) solution Deep Neuro has started generating non-reimbursed revenue."

Regarding the larger-than-expected operating loss, researcher Jo analyzed, "Among the sales for secondary batteries, the proportion of hardware with a relatively high cost ratio was high," and "labor costs also increased due to hiring personnel to expand the medical AI business."

He forecasted, "We will be able to confirm the growth trend in performance depending on the results of the medical AI business in the second half of this year," and "We expect sales to increase as the number of hospitals applying non-reimbursed services for the brain aneurysm screening solution Deep Neuro expands." He also emphasized, "The number of hospitals adopting Deep Neuro was 23 as of last month," adding, "and the goal is to introduce it to 80 hospitals within this year."

Sales are estimated to reach 27 billion KRW and operating profit 7 billion KRW next year. Sales would increase by 86.2% compared to this year's forecast, and operating profit would turn positive.

This content was produced with the assistance of AI translation services.